Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.40 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.40 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31287796 | 0.82 | ALOX5 (0.50) | GRM5NUDT1PRMT5ALOX5 | |
| SCHEMBL14744985 | 0.82 | ALOX5 (0.50) | GRM5NUDT1PRMT5ALOX5 | |
| SCHEMBL1899392 | 0.81 | NUDT1 (0.51) | GABRG2GABRB3GABRA5GABRA3NUDT1 | |
| SCHEMBL1901652 | 0.81 | GRM5 (0.48) | GRM5GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL8384805 | 0.79 | PIN1 (0.47) | GRM5NUDT1PRMT5ALOX5HRH4 | |
| SCHEMBL8773184 | 0.78 | MAOB (0.51) | GRM5NUDT1PRMT5ALOX5HRH4 | |
| SCHEMBL31287990 | 0.78 | MAOB (0.51) | GRM5NUDT1PRMT5ALOX5HRH4 | |
| SCHEMBL603696 | 0.77 | NUDT1 (0.48) | GRM5NUDT1PRMT5ALOX5MCL1 | |
| SCHEMBL3930094 | 0.77 | NUDT1 (0.62) | GRM5NUDT1PRMT5HRH4 | |
| SCHEMBL24461268 | 0.77 | GRM5 (0.45) | GRM5GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455477-B2 | Therapeutic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110207711-A1 | Therapeutic Compounds | MSD K.K. (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2320907-A1 | THERAPEUTIC COMPOUNDS | Merck & Co., Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010017047-A1 | THERAPEUTIC COMPOUNDS | MERCK & CO., INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207711-A1 | Therapeutic Compounds | WEE2, MARK3, WEE1 | GRM5 1233/4885GABRG2 3154/4885GABRB3 2786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.